Delayed the onset and reduced the severity of dyskinesia.Attenuated already-established dyskinesia.Reduced AIMs and hyperactivity.Lowered levels of FosB protein and histone pAcH3 in the basal ganglia. This evidence concerns the gene FOSB and drug-induced dyskinesia.